Computational biotech, run by agents
The first fully agentic computational biotechnology company.
Aliquant Bio deploys autonomous AI agents that read the literature, pick targets, design molecules and run in-silico experiments — starting with antivirals for hand, foot & mouth disease in young children.
Platform
An autonomous design–make–test loop, in silico.
Specialised agents hand work to each other, with every decision logged and reviewable by a human.
-
01
Read
Literature agents mine papers, patents and structural databases to map what is known about each viral target.
-
02
Hypothesise
Reasoning agents rank targets and binding pockets, and propose what to test next and why.
-
03
Design
Generative and ML scoring models propose, filter and optimise candidate molecules.
-
04
Validate
Docking, ADMET prediction and critique agents stress-test candidates before anything reaches a wet lab.
Pipeline
Hand, foot & mouth disease.
HFMD causes large seasonal outbreaks among young children, especially across the Asia‑Pacific region. Most cases are mild, but enterovirus A71 can cause severe neurological disease — and there is still no approved antiviral treatment. That is the gap we are going after first.
Programs shown are placeholders — edit the PIPELINE list in main.js.
Machine learning
Our model.
A short description of what your model predicts, what it was trained on, and why it matters for the pipeline. Replace this paragraph with your own summary.
- —ROC‑AUC
- —Training compounds
- —Inference time
Writing
Notes from the lab that isn't a lab.
Follow along
New essays on agentic science, ML for drug discovery and the HFMD program.
Collaborate with Aliquant.
Wet-lab partners, clinicians working on paediatric enteroviruses, and investors — we'd love to hear from you.
hello@aliquant.bio